Stryker Corporation

    Jurisdiction
    United States
    LEI
    5493002F0SC4JTBU5137
    ISIN
    US8636671013 (SYK)
    Sectors
    1. Healthcare
    2. Medical - Devices

    Scores

    InsiderPie Expert Score
    70 / 100
    Better than peer group:
    53 / 100
    Fair value (Benjamin Graham formula)
    €284.91 11.5% overvalued
    Financial strength (Piotroski F-Value)
    6 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Quick analysis

    Stryker Corporation – Leading Medical Device Company with a Broad Portfolio

    Brief Summary for Investors: Stryker is an established US medical device company with a market capitalization of approximately $128 billion. The company serves two main segments: Orthopedics/Spine, MedSurg, and Neurotechnology, and markets its products to healthcare facilities worldwide.

    Development The share price has shown a clear upward trend over the past five years, driven by consistent revenue and profit growth. Annual revenue increased from $14.4 billion (2020) to $20.5 billion (2023). However, the latest quarterly figures show some volatility, with a significant decline in revenue and EBITDA in the most recent reported quarter (Q1 2025) compared to the previous quarter (Q4 2024). Profitability ratios (ROE, ROA) are currently moderate, and the debt-to-equity ratio of 1.2 reflects reasonable but substantial leverage.

    Opportunities:

    • Demographic trend: The aging global population is driving long-term demand for elective procedures such as hip and knee replacements.
    • Broad portfolio: Diversification across multiple medical specialties reduces dependence on a single market and offers cross-selling opportunities.
    • Innovation: Stryker's focus on technological advances, particularly in robotics (surgical navigation systems) and minimally invasive procedures, secures competitive advantages.

    Risks:

    • Regulatory interventions: The healthcare sector is vulnerable to regulatory changes and pricing pressure from health insurers and governments.
    • Economic Sensitivity: Elective surgeries can be postponed during economic downturns, which can negatively impact revenues in the short term.
    • Operational Volatility: Recent quarterly results indicate potential operational irregularities or seasonal effects that warrant monitoring.

    Additional Notes: In the last 60 days, sales were reported by a politician, several senior executives, and one director. Insider transaction volumes were substantial, which can be considered an indicator for close monitoring.

    Conclusion: Stryker is a high-quality, profitable company in a structurally growing market. The long-term fundamentals are strong, but the latest quarterly results raise questions about short-term operating performance. The current quarter-on-quarter decline in revenue and profitability warrants increased attention. Investors should await the next quarterly reports to assess whether this represents a seasonal blip or the beginning of a trend break. The long-term investment case remains intact due to demographic drivers and market positioning.

    Read full AI analysis

    Created

    Profile

    Stryker Corporation operates as a medical technology company. Read full profile

    Fundamentals

    Net revenue
    €20.32B
    Gross margin
    63.8%
    EBIT
    €3.30B
    EBIT margin
    16.2%
    Net income
    €2.49B
    Net margin
    12.3%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €23.14B +13.9% €4.95B +98.9%
    €25.09B +8.4% €5.54B +11.9%
    €27.38B +9.1% €6.32B +14.2%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    Last dividend amount
    $0.84
    Ex date
    Payment date
    Dividend payout ratio
    42.9%

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Menon Viju Group President -500 $390.61 -$195.31K
    Fletcher Robert S VP, Chief Legal Officer -1.8K $393.07 -$701.63K
    STRYKER RONDA E N/A -200K $376.45 -$75.29M

    Congress transactions

    Name Transaction date Value
    Thomas Kean September 18, 2025 $1.00K–$15.00K
    Thomas Kean August 20, 2025 $15.00K–$50.00K
    Thomas Kean July 16, 2025 $15.00K–$50.00K
    Jefferson Shreve June 22, 2025 $50.00K–$100.00K
    Julie Johnson May 14, 2025 $1.00K–$15.00K

    Investor transactions

    Name Shares Value Last change Change type
    Terry Smith 5.1M $1.89B -265K Sell
    Ray Dalio 15K $5.76M -24K Sell

    Earnings Calls

    Add to watchlist

    Notifications